Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9 (2), 72-3

Multiple Sclerosis in 2012: Novel Therapeutic Options and Drug Targets in MS

Affiliations
Review

Multiple Sclerosis in 2012: Novel Therapeutic Options and Drug Targets in MS

Axel Methner et al. Nat Rev Neurol.

Erratum in

  • Nat Rev Neurol. 2013 May;9(5):240

Abstract

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

References

    1. Nature. 2012 Aug 23;488(7412):508-11 - PubMed
    1. PLoS One. 2012;7(3):e33797 - PubMed
    1. J Neurol Sci. 2011 Jul 15;306(1-2):173-9 - PubMed
    1. N Engl J Med. 2012 Sep 20;367(12):1087-97 - PubMed
    1. Brain. 2011 Mar;134(Pt 3):678-92 - PubMed

MeSH terms

LinkOut - more resources

Feedback